IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5 , IL-18 , IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research.